UnknownNCT04429620

Prospective Assay for SARS-CoV-2 (COVID-19) Antibody Detection Indirectly by Immunofluorescence: SARS-CoV2 IIF Method

Studying Severe acute respiratory syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Szeged University
Principal Investigator
Katalin Burián, MD
University of Szeged, Institute of Clinical Microbilogy
Intervention
Immunfluorescence(diagnostic_test)
Enrollment
100 target
Eligibility
18 years · All sexes
Timeline
20202020

Study locations (1)

Collaborators

Bilogical Research Centre, Szeged

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04429620 on ClinicalTrials.gov

Other trials for Severe acute respiratory syndrome

Additional recruiting or active studies for the same condition.

See all trials for Severe acute respiratory syndrome

← Back to all trials